|4.25|| -0.05 / -1.16%|
Trovagene, Inc. is a molecular diagnostic company, which focuses on the development and commercialization of a proprietary urine-based molecular diagnostic technology for use in disease detection and monitoring across a variety of medical disciplines. Its focus is to leverage its novel cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes developing collaborations in the areas of infectious disease, transplant medicine and prenatal diagnostics. The company's proprietary urine-based molecular diagnostic tests are designed to detect specific nucleic acids in urine which are known as transrenal DNA and RNA. Its technology is applied in various testing, such as tumor detection and monitoring, prenatal genetic testing, infectious diseases, tissue transplantation, and forensic identification, as well as for patient selection in clinical trials. Trovagene was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
|Bill Welch||Chief Executive Officer & Director|
|Elizabeth Anderson||Vice President-Finance & Administration|
|Mark Erlander||Chief Scientific Officer|
|Vlada Melnikova||Vice President-Clinical & Translational Affairs|
|Karsten Schmidt||Chief Technology Officer|